Biologic Medicines-Focused Comera Life Sciences Turns To SPAC For NASDAQ Debut

Comera Life Sciences Inc has agreed to go public through a merger with OTR Acquisition Corp OTRA, a blank-check company.

• The combined company will have an initial equity value of about $258.4 million. The companies said it would provide about $107 million in gross cash proceeds.
• All 12.6 million shares will be issued to Comera stockholders at an implied value of $10 per share. 
• The transaction also includes a potential earn-out to Comera shareholders, including 3.15 million more shares.
• The SPAC is led by investor and entrepreneur Nicholas J. Singer, who serves as chairman and CEO. 
• After the transaction closes, Jeff Hackman, Comera’s CEO, will lead the combined company.
• Woburn, Massachusetts-based Comera Life, is developing new biologic medicines to improve safety and convenience for patients, switching from intravenous to subcutaneous injections.
• Comera applies its formulation platform, SQore, to develop a portfolio of proprietary subcutaneous (SQ) therapeutics. 
• Comera will also continue collaborating with pharmaceutical and biotechnology companies, applying its SQore platform to partners’ biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
• The merger will close in Q2 FY22.
• Price Action: OTRA shares are trading 0.13% higher at $10.17 during the market session on the last check Monday.